Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BB BIOTECH AG-REG. We currently have 1 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
BB BIOTECH AG-REG
BB BIOTECH AG-REG
Sector specialist with high distribution policy
09 Feb 16
BB Biotech (BION) seeks to achieve long-term capital growth by investing in fast-growing biotech companies. A discount management programme adopted in 2012 allows it to return 5% of its value each year as a capital distribution, resulting in an unusually high yield (6.4% at 3 February) for a fund investing in a low-yielding sector. Biotech has performed strongly and BION has beaten the benchmark NASDAQ Biotech index in three of the last five years, although it has underperformed in a sharp sell-off since the start of 2016. The fund invests globally and across the size spectrum, with a concentrated portfolio heavily weighted towards 5-8 core holdings. It is currently focused more on primary care end-markets, where the lowercost, higher-volume model is less affected by political pressure on pricing.
19 Jan 17
Aggregated Micro Power* (AMPH): Funding for first peaking power plant project (CORP) | The Mission Marketing Group* (TMMG): Positive trading update (CORP) | Cello (CLL): Increasingly backed by, and leveraging, technology (BUY) | 4imprint (FOUR): Growth backed by strong cash flow continues (BUY) | Allergy Therapeutics (AGY): Positive trading update and market share gains drive upgrades (BUY) | Shanta Gold (SHG): Q4 operating results (BUY) | Sound Energy (SOU): Tendrara extended well test result (BUY) | Revolution Bars (RBG): Price target increase (BUY)
Interims results – reassuringly positive
24 Jan 17
Scientific Digital Imaging reported interim results to 31 October 2016, with adjusted EPS of 0.73p, an increase of 21%. Results included a first-time contribution from Sentek, acquired on 28 October 2015, which more than offset a c3% decline in the underlying business. Sentek accounts for c30% of group gross profits and continues to perform in line with expectations. New product development and recent product launches in Synoptics, combined with the contribution from Astles Control Systems (acquired January 2017) should drive improved profitability and free cash flow. We leave forecasts and target price unchanged at 20p.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
ACTUAL EXPERIENCE PLC (ACT LN) | BAGIR GRP LTD (BAGR LN) | BIOQUELL (BQE LN) | BROWN(N.)GROUP (BWNG LN) | CARADOR INCOME FUND PLC (CIFU LN) | HALFORDS GROUP (HFD LN) | NCC GROUP (NCC LN) | ST IVES PLC (SIV LN) | SUMMIT THERAPEUTICS PLC (SUMM LN) | WILMINGTON PLC (WIL LN)
N+1 Singer - Best Ideas 2017 - Top picks
04 Jan 17
Today we publish our Best Ideas for 2017 - 12 stocks that we believe have excellent prospects in the current year together with a detailed discussion of what we see as the key sector and market themes for 2017. Our top picks are Cineworld, Elementis, Herald Investment Trust, Hill & Smith, IQE, MySale, Redde, ReNeuron, RhythmOne, SDL, Servelec and Severfield.
N+1 Singer - Midatech Pharma - FY trading update: revenue ahead of estimates
20 Jan 17
Midatech’s FY trading update indicates revenue for the period of c. £9.0m, ahead of our £8.0m estimate. The £16.7m (gross) capital raise announced in October allows Midatech to accelerate development of its key programmes. We continue to expect data from a gold nanoparticle (GNP) enabled Phase I diabetes vaccine trial in 2017, followed by the start of clinical trials in brain and liver cancer by early 2018. In addition, Q-Octreotide in our view represents a significant near-term licensing opportunity. We reiterate our Buy recommendation.
N+1 Singer - Sinclair Pharma - FY trading update: revenue ahead of estimates
17 Jan 17
Sinclair’s FY trading update indicates revenue for the period of £37.8m, ahead of our £35.4m estimate. Cash at period-end was slightly below our expectations at £16.8m vs. our £18.5m forecast. Sales of the five key products are in line or slightly ahead of estimates. Importantly, the early indications are positive for the US rollout of Silhouette Instalift™ with practitioner training ahead of schedule. Overall a positive trading update: we reiterate our Buy recommendation and 42p target price.